Literature DB >> 15905981

[Symptoms, risk factors, and etiology of transient ischemic attack and stroke].

C H Nolte1, J Müller-Nordhorn, G J Jungehülsing, K Rossnagel, A Reich, M Klein, S N Willich, A Villringer.   

Abstract

BACKGROUND: It is unclear whether clinical signs and symptoms differ in the presentation of transient ischemic attack (TIA) and stroke, apart from temporal dynamics.
METHODS: Signs and symptoms of patients diagnosed with TIA or stroke were prospectively collected and compared by means of an age-adjusted logistic regression analysis. Risk factors, prehospital medication, and diagnostic workup were obtained from the charts.
RESULTS: Four hundred five patients diagnosed with stroke (68+/-12 years old, 45% female) and 143 diagnosed with TIA (64+/-14 years old, 48% female) were included. Signs and symptoms of patients with TIA were less often "classic" such as paresis (48% vs 71%, P<0.001) or sensory loss (38% vs 48%, P=0.03). The etiology of TIA was more often classified as "undetermined" (57% vs 46%, P<0.05).
CONCLUSIONS: Transient ischemic attack needs special attention and intensive diagnostic workup, because it bears a considerable risk of death and disability but presents less often with classic signs and symptoms and its etiology often remains undetermined.

Entities:  

Mesh:

Year:  2005        PMID: 15905981     DOI: 10.1007/s00115-005-1928-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  21 in total

1.  Comparison of population-based models of risk factors for TIA and ischemic stroke.

Authors:  J P Whisnant; R D Brown; G W Petty; W M O'Fallon; J D Sicks; D O Wiebers
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

2.  Transient ischemic attack--proposal for a new definition.

Authors:  Gregory W Albers; Louis R Caplan; J Donald Easton; Pierre B Fayad; J P Mohr; Jeffrey L Saver; David G Sherman
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

Review 3.  [Risk factors in ischemic stroke. Review of evidence in primary prevention].

Authors:  M Weih; J Müller-Nordhorn; N Amberger; F Masuhr; F Lürtzing; J P Dreier; A Hetzel
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

4.  Diffusion MRI in patients with transient ischemic attacks.

Authors:  C S Kidwell; J R Alger; F Di Salle; S Starkman; P Villablanca; J Bentson; J L Saver
Journal:  Stroke       Date:  1999-06       Impact factor: 7.914

5.  Etiopathogenesis of transient ischemic attacks and minor ischemic strokes: a community-based study in Segovia, Spain.

Authors:  A P Sempere; J Duarte; C Cabezas; L E Clavería
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

6.  Transient ischemic attacks are more than "ministrokes".

Authors:  Michael Daffertshofer; Orell Mielke; Arne Pullwitt; Matthias Felsenstein; Michael Hennerici
Journal:  Stroke       Date:  2004-10-14       Impact factor: 7.914

7.  Advertising strategies to increase public knowledge of the warning signs of stroke.

Authors:  Frank L Silver; Frank Rubini; Diane Black; Corinne S Hodgson
Journal:  Stroke       Date:  2003-07-10       Impact factor: 7.914

8.  [Strategies for early admission of stroke patients].

Authors:  B Müffelmann; J Glahn; S Kunz; O Busse
Journal:  Nervenarzt       Date:  1995-02       Impact factor: 1.214

9.  Comparison of risk factors in patients with transient and prolonged eye and brain ischemic syndromes.

Authors:  Gillian E Mead; Stephanie C Lewis; Joanna M Wardlaw; Martin S Dennis
Journal:  Stroke       Date:  2002-10       Impact factor: 7.914

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

View more
  1 in total

1.  [Management of acute ischemic stroke].

Authors:  C H Nolte; M Endres
Journal:  Internist (Berl)       Date:  2012-05       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.